BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

816 related articles for article (PubMed ID: 33479445)

  • 1. Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition.
    Cullen NC; Mälarstig AN; Stomrud E; Hansson O; Mattsson-Carlgren N
    Sci Rep; 2021 Jan; 11(1):1965. PubMed ID: 33479445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals.
    Simrén J; Brum WS; Ashton NJ; Benedet AL; Karikari TK; Kvartsberg H; Sjons E; Lussier FZ; Chamoun M; Stevenson J; Hopewell R; Pallen V; Ye K; Pascoal TA; Zetterberg H; Rosa-Neto P; Blennow K
    Alzheimers Res Ther; 2022 Dec; 14(1):192. PubMed ID: 36544221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glial activation and inflammation along the Alzheimer's disease continuum.
    Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
    J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study.
    Zhang H; Lyu D; Jia J;
    J Alzheimers Dis; 2022; 85(4):1441-1452. PubMed ID: 34958042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.
    Okonkwo OC; Alosco ML; Griffith HR; Mielke MM; Shaw LM; Trojanowski JQ; Tremont G;
    Arch Neurol; 2010 Jun; 67(6):688-96. PubMed ID: 20558388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol metabolites and plant sterols in cerebrospinal fluid are associated with Alzheimer's cerebral pathology and clinical disease progression.
    Jahn T; Clark C; Kerksiek A; Lewczuk P; Lütjohann D; Popp J
    J Steroid Biochem Mol Biol; 2021 Jan; 205():105785. PubMed ID: 33171206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NEURONORMA Cognitive Battery Associations with Cerebrospinal Fluid Amyloid-β and Tau Levels in the Continuum of Alzheimer's Disease.
    García-Escobar G; Puig-Pijoan A; Puente-Periz V; Fernández-Lebrero A; María Manero R; Navalpotro-Gómez I; Suárez-Calvet M; Grau-Rivera O; Contador-Muñana J; Cascales-Lahoz D; Duran-Jordà X; Boltes N; Pont-Sunyer MC; Ortiz-Gil J; Carrillo-Molina S; López-Villegas MD; Abellán-Vidal MT; Martínez-Casamitjana MI; Hernández-Sánchez JJ; Padrós-Fluvià A; Peña-Casanova J; Sánchez-Benavides G
    J Alzheimers Dis; 2023; 92(4):1303-1321. PubMed ID: 37038810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
    Wen C; Bi YL; Hu H; Huang SY; Ma YH; Hu HY; Tan L; Yu JT
    J Alzheimers Dis; 2022; 85(3):1143-1151. PubMed ID: 34924386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
    J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Allergy on Immunoglobulins and Amyloid-β in the Cerebrospinal Fluid of Patients with Alzheimer's Disease.
    Sarlus H; Eyjolfsdottir H; Eriksdotter M; Oprica M; Schultzberg M
    J Alzheimers Dis; 2015; 48(2):495-505. PubMed ID: 26402013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment.
    Newton P; Tchounguen J; Pettigrew C; Lim C; Lin Z; Lu H; Moghekar A; Albert M; Soldan A;
    J Alzheimers Dis; 2023; 92(1):323-339. PubMed ID: 36744337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study.
    Vrillon A; Mouton-Liger F; Martinet M; Cognat E; Hourregue C; Dumurgier J; Bouaziz-Amar E; Brinkmalm A; Blennow K; Zetterberg H; Hugon J; Paquet C
    Alzheimers Res Ther; 2022 May; 14(1):71. PubMed ID: 35606871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
    Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
    Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.